Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Cyclin-dependent kinases (CDK) 4 and 6 are viable therapeutic target in HER2-positive breast cancer models that functions downstream of HER2.
Tissue based markers are available to direct rational utilisation of selective CDK4/6 inhibitor palbociclib, according to the study performed in a combination of cell culture, mouse models and human primary tumour explants.
The results were presented by Dr Erik Knudsen of the University of Texas Southwestern, Dallas, USA.
Read the article in full here.
Source: ESMO
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.